Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1.

Cho HS, Kelly JD, Hayami S, Toyokawa G, Takawa M, Yoshimatsu M, Tsunoda T, Field HI, Neal DE, Ponder BA, Nakamura Y, Hamamoto R.

Neoplasia. 2011 Aug;13(8):676-84.

2.

Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells.

Lu Z, Tian Y, Salwen HR, Chlenski A, Godley LA, Raj JU, Yang Q.

Anticancer Drugs. 2013 Jun;24(5):484-93. doi: 10.1097/CAD.0b013e32835ffdbb.

3.

BIX-01294 induces autophagy-associated cell death via EHMT2/G9a dysfunction and intracellular reactive oxygen species production.

Kim Y, Kim YS, Kim DE, Lee JS, Song JH, Kim HG, Cho DH, Jeong SY, Jin DH, Jang SJ, Seol HS, Suh YA, Lee SJ, Kim CS, Koh JY, Hwang JJ.

Autophagy. 2013 Dec;9(12):2126-39. doi: 10.4161/auto.26308.

PMID:
24322755
4.

Inhibition of EHMT2/G9a epigenetically increases the transcription of Beclin-1 via an increase in ROS and activation of NF-κB.

Park SE, Yi HJ, Suh N, Park YY, Koh JY, Jeong SY, Cho DH, Kim CS, Hwang JJ.

Oncotarget. 2016 Jun 28;7(26):39796-39808. doi: 10.18632/oncotarget.9290.

6.
7.

The novel prognostic marker, EHMT2, is involved in cell proliferation via HSPD1 regulation in breast cancer.

Kim SK, Kim K, Ryu JW, Ryu TY, Lim JH, Oh JH, Min JK, Jung CR, Hamamoto R, Son MY, Kim DS, Cho HS.

Int J Oncol. 2019 Jan;54(1):65-76. doi: 10.3892/ijo.2018.4608. Epub 2018 Oct 26.

8.

Inhibition of EHMT2 Induces a Robust Antiviral Response Against Foot-and-Mouth Disease and Vesicular Stomatitis Virus Infections in Bovine Cells.

Singh N, Ramĩrez-Carvajal L, de Los Santos T, Golding MC, Long CR.

J Interferon Cytokine Res. 2016 Jan;36(1):37-47. doi: 10.1089/jir.2015.0006. Epub 2015 Sep 29.

9.

EHMT2 is a metastasis regulator in breast cancer.

Kim K, Son MY, Jung CR, Kim DS, Cho HS.

Biochem Biophys Res Commun. 2018 Feb 5;496(2):758-762. doi: 10.1016/j.bbrc.2018.01.074. Epub 2018 Jan 11.

PMID:
29337058
10.

Euchromatic histone methyltransferase 2 inhibitor, BIX-01294, sensitizes human promyelocytic leukemia HL-60 and NB4 cells to growth inhibition and differentiation.

Savickiene J, Treigyte G, Stirblyte I, Valiuliene G, Navakauskiene R.

Leuk Res. 2014 Jul;38(7):822-9. doi: 10.1016/j.leukres.2014.04.003. Epub 2014 Apr 18.

PMID:
24832370
11.

Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway.

Toyokawa G, Cho HS, Masuda K, Yamane Y, Yoshimatsu M, Hayami S, Takawa M, Iwai Y, Daigo Y, Tsuchiya E, Tsunoda T, Field HI, Kelly JD, Neal DE, Maehara Y, Ponder BA, Nakamura Y, Hamamoto R.

Neoplasia. 2011 Oct;13(10):887-98.

12.

Histone methyltransferase G9a and H3K9 dimethylation inhibit the self-renewal of glioma cancer stem cells.

Tao H, Li H, Su Y, Feng D, Wang X, Zhang C, Ma H, Hu Q.

Mol Cell Biochem. 2014 Sep;394(1-2):23-30. doi: 10.1007/s11010-014-2077-4. Epub 2014 May 16.

PMID:
24833465
13.

The histone methyltransferase Wolf-Hirschhorn syndrome candidate 1-like 1 (WHSC1L1) is involved in human carcinogenesis.

Kang D, Cho HS, Toyokawa G, Kogure M, Yamane Y, Iwai Y, Hayami S, Tsunoda T, Field HI, Matsuda K, Neal DE, Ponder BA, Maehara Y, Nakamura Y, Hamamoto R.

Genes Chromosomes Cancer. 2013 Feb;52(2):126-39. doi: 10.1002/gcc.22012. Epub 2012 Sep 25.

PMID:
23011637
14.

Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1α and APC2 gene expression in non-small cell lung cancer.

Zhang K, Wang J, Yang L, Yuan YC, Tong TR, Wu J, Yun X, Bonner M, Pangeni R, Liu Z, Yuchi T, Kim JY, Raz DJ.

Mol Cancer. 2018 Oct 22;17(1):153. doi: 10.1186/s12943-018-0896-8.

15.

Abnormal histone H3K9 dimethylation but normal dimethyltransferase EHMT2 expression in cloned sheep embryos.

Fu L, Zhang J, Yan FX, Guan H, An XR, Hou J.

Theriogenology. 2012 Dec;78(9):1929-38. doi: 10.1016/j.theriogenology.2012.07.017. Epub 2012 Oct 8.

PMID:
23058792
16.

Inhibition of euchromatic histone methyltransferase 1 and 2 sensitizes chronic myeloid leukemia cells to interferon treatment.

Loh SW, Ng WL, Yeo KS, Lim YY, Ea CK.

PLoS One. 2014 Jul 31;9(7):e103915. doi: 10.1371/journal.pone.0103915. eCollection 2014.

17.

EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression.

Renneville A, Van Galen P, Canver MC, McConkey M, Krill-Burger JM, Dorfman DM, Holson EB, Bernstein BE, Orkin SH, Bauer DE, Ebert BL.

Blood. 2015 Oct 15;126(16):1930-9. doi: 10.1182/blood-2015-06-649087. Epub 2015 Aug 28.

18.

Pharmacological and transcriptional inhibition of the G9a histone methyltransferase suppresses proliferation and modulates redox homeostasis in human microvascular endothelial cells.

Wojtala M, Macierzyńska-Piotrowska E, Rybaczek D, Pirola L, Balcerczyk A.

Pharmacol Res. 2018 Feb;128:252-263. doi: 10.1016/j.phrs.2017.10.014. Epub 2017 Nov 4.

PMID:
29113759
19.

G9a inhibition induced PKM2 regulates autophagic responses.

Ahmad F, Dixit D, Joshi SD, Sen E.

Int J Biochem Cell Biol. 2016 Sep;78:87-95. doi: 10.1016/j.biocel.2016.07.009. Epub 2016 Jul 11.

PMID:
27417236
20.

The histone methyltransferase G9a: a new therapeutic target in biliary tract cancer.

Mayr C, Helm K, Jakab M, Ritter M, Shrestha R, Makaju R, Wagner A, Pichler M, Beyreis M, Staettner S, Jaeger T, Klieser E, Kiesslich T, Neureiter D.

Hum Pathol. 2018 Feb;72:117-126. doi: 10.1016/j.humpath.2017.11.003. Epub 2017 Nov 11.

PMID:
29133140

Supplemental Content

Support Center